KRAS and neoplasm: Non-A-on label biomarkers (A-off label, B-on label and B-off label) showed a modest and tumour-type-dependent metastatic increase, which was mainly linked to the increased alteration frequency of KRAS exon 2 mutations and CDKN2A loss in advanced tumour stages (Extended Data Fig. 8b).